SCHEMBL24868656

SCHEMBL24868656

CCc1cnc(C)cc1O

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NOS3 P29474 1/20 0.44
NOS1 P29475 1/20 0.44
NOS2 P35228 1/20 0.44
SLC6A2 P23975 4/20 0.40
SLC6A4 P31645 4/20 0.40
SLC6A3 Q01959 3/20 0.40
DHFR P00374 1/20 0.37
ALOX15 P16050 1/20 0.36
ALOX12 P18054 1/20 0.36
MCL1 Q07820 2/20 0.36
UHRF1 Q96T88 1/20 0.35
GABRP O00591 1/20 0.35
GABRD O14764 1/20 0.35
GABRA1 P14867 1/20 0.35
GABRB1 P18505 1/20 0.35
GABRG2 P18507 1/20 0.35
GABRB3 P28472 1/20 0.35
GABRA5 P31644 1/20 0.35
GABRA3 P34903 1/20 0.35
GABRA2 P47869 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6276317 0.83 NOS3 (0.39) NOS3NOS1NOS2SLC6A2SLC6A4
SCHEMBL7443325 0.81 LMNA (0.42) NOS3NOS1NOS2SLC6A2SLC6A4
SCHEMBL16201837 0.80 NOS3 (0.41) NOS3NOS1NOS2DHFRALOX15
SCHEMBL7117731 0.79 NOS3 (0.48) NOS3NOS1NOS2SLC6A2SLC6A4
SCHEMBL7120097 0.77 NOS3 (0.63) NOS3NOS1NOS2SLC6A2SLC6A4
SCHEMBL25652153 0.77 NOS3 (0.42) NOS3NOS1NOS2SLC6A2SLC6A4
SCHEMBL28182810 0.76 GCK (0.38) SLC6A2SLC6A4SLC6A3MAPTLMNA
SCHEMBL15760110 0.75 ALOX15 (0.38) NOS3NOS1NOS2DHFRALOX15
SCHEMBL21120987 0.74 NOS3 (0.44) NOS3NOS1NOS2SLC6A2SLC6A4
SCHEMBL17778630 0.74 NOS3 (0.39) NOS3NOS1NOS2SLC6A2SLC6A4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230227474-A1 COMPOSITIONS AND METHODS FOR CORRECTION OF ABERRANT SPLICING SKYHAWK THERAPEUTICS, INC. (US) 2023-07-20 US disclosed
US-20230008867-A1 METHODS AND COMPOSITIONS FOR MODULATING SPLICING SKYHAWK THERAPEUTICS, INC. 2023-01-12 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230008867-A1 METHODS AND COMPOSITIONS FOR MODULATING SPLICING RBM17, SF3B1, SNRPA1 NOS3 1924/4885NOS1 1869/4885NOS2 2491/4885
US-20230227474-A1 COMPOSITIONS AND METHODS FOR CORRECTION OF ABERRANT SPLICING RBM17, SF3B1, SF3B5 NOS3 3265/4885NOS1 3154/4885NOS2 3689/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.